Panacea Biotec Limited
Panacea Biotec Limited Fundamental Analysis
Panacea Biotec Limited (PANACEABIO.NS) shows weak financial fundamentals with a PE ratio of -254.61, profit margin of -1.28%, and ROE of -0.94%. The company generates $6.1B in annual revenue with weak year-over-year growth of 1.30%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 20.5/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze PANACEABIO.NS's fundamental strength across five key dimensions:
Efficiency Score
WeakPANACEABIO.NS struggles to generate sufficient returns from assets.
Valuation Score
ModeratePANACEABIO.NS shows balanced valuation metrics.
Growth Score
WeakPANACEABIO.NS faces weak or negative growth trends.
Financial Health Score
ExcellentPANACEABIO.NS maintains a strong and stable balance sheet.
Profitability Score
WeakPANACEABIO.NS struggles to sustain strong margins.
Key Financial Metrics
Is PANACEABIO.NS Expensive or Cheap?
P/E Ratio
PANACEABIO.NS trades at -254.61 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, PANACEABIO.NS's PEG of 33.38 indicates potential overvaluation.
Price to Book
The market values Panacea Biotec Limited at 2.40 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 71.49 times EBITDA. This signals the market has high growth expectations.
How Well Does PANACEABIO.NS Make Money?
Net Profit Margin
For every $100 in sales, Panacea Biotec Limited keeps $-1.28 as profit after all expenses.
Operating Margin
Core operations generate -11.18 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-0.94 in profit for every $100 of shareholder equity.
ROA
Panacea Biotec Limited generates $-0.62 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Panacea Biotec Limited generates limited operating cash flow of $-7.70M, signaling weaker underlying cash strength.
Free Cash Flow
Panacea Biotec Limited generates weak or negative free cash flow of $-260.70M, restricting financial flexibility.
FCF Per Share
Each share generates $-4.26 in free cash annually.
FCF Yield
PANACEABIO.NS converts -1.32% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-254.61
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
33.38
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.40
vs 25 benchmark
P/S Ratio
Price to sales ratio
3.27
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.03
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.54
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.01
vs 25 benchmark
ROA
Return on assets percentage
-0.01
vs 25 benchmark
ROCE
Return on capital employed
-0.07
vs 25 benchmark
How PANACEABIO.NS Stacks Against Its Sector Peers
| Metric | PANACEABIO.NS Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -254.61 | 28.45 | Better (Cheaper) |
| ROE | -0.94% | 763.00% | Weak |
| Net Margin | -1.28% | -45265.00% (disorted) | Weak |
| Debt/Equity | 0.03 | 0.34 | Strong (Low Leverage) |
| Current Ratio | 1.54 | 2795.60 | Neutral |
| ROA | -0.62% | -16588.00% (disorted) | Weak |
PANACEABIO.NS outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Panacea Biotec Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
4.34%
Industry Style: Defensive, Growth, Innovation
GrowingEPS CAGR
95.68%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
9.22%
Industry Style: Defensive, Growth, Innovation
Growing